Additionally, pairing EEDNV with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) to amplify anti-tumor immunity, as preclinical data support synergy between mitochondrial-targeted therapies and immunotherapy (Shang et al., 2023). This evidence concerns the gene CD274 and neoplasm.